Refining Treatment Timelines and Immunotherapy Strategies in Early-Stage NSCLC: Jonathan Thompson, MD, MS

Jonathan Thompson, MD, MS, highlighted that reducing delays in molecular testing and treatment initiation is critical for improving lung cancer outcomes, and that clinical trial data suggest immunotherapy duration can often be safely de-escalated in patients who achieve a complete pathologic response.